<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719143</url>
  </required_header>
  <id_info>
    <org_study_id>831841</org_study_id>
    <nct_id>NCT04719143</nct_id>
  </id_info>
  <brief_title>Effects of Insomnia Treatment on Metabolism in Patients With Depression</brief_title>
  <official_title>Effects of Insomnia Treatment on Metabolism in Patients With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will examine changes in metabolism and depressive symptoms after receiving CBT-I&#xD;
      in 30 subjects with insomnia disorder and MDD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomic Assays</measure>
    <time_frame>Baseline (week 0)</time_frame>
    <description>Blood samples will be collected at enrollment and 2 weeks following the completion of CBT-I to examine metabolic markers of response to CBT-I. We will use NMR Spectroscopy to examine serum metabolite changes in patients with insomnia before and after CBT-I, in comparison with therapy control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolomic Assays</measure>
    <time_frame>2 weeks post-treatment (week 10 on average)</time_frame>
    <description>Blood samples will be collected at enrollment and 2 weeks following the completion of CBT-I to examine metabolic markers of response to CBT-I. We will use NMR Spectroscopy to examine serum metabolite changes in patients with insomnia before and after CBT-I, in comparison with therapy control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>Baseline (week 0)</time_frame>
    <description>A 7-item (0-4 Likert scale) measure with a total score of 28. The norms for the scale are: 0-7 represents no clinically significant insomnia; 8-14 represents sub-threshold insomnia; 15-21 represents clinical insomnia (moderate severity); 21-28 represents clinical insomnia (severe). The Insomnia Severity Index, the primary outcome of Aim 1, demonstrates good internal consistency (alpha=.74) and is routinely used as the primary outcome measure in insomnia RCTs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>2 weeks post-treatment (week 10 on average)</time_frame>
    <description>A 7-item (0-4 Likert scale) measure with a total score of 28. The norms for the scale are: 0-7 represents no clinically significant insomnia; 8-14 represents sub-threshold insomnia; 15-21 represents clinical insomnia (moderate severity); 21-28 represents clinical insomnia (severe). The Insomnia Severity Index, the primary outcome of Aim 1, demonstrates good internal consistency (alpha=.74) and is routinely used as the primary outcome measure in insomnia RCTs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>3 months post-treatment (week 20 on average)</time_frame>
    <description>A 7-item (0-4 Likert scale) measure with a total score of 28. The norms for the scale are: 0-7 represents no clinically significant insomnia; 8-14 represents sub-threshold insomnia; 15-21 represents clinical insomnia (moderate severity); 21-28 represents clinical insomnia (severe). The Insomnia Severity Index, the primary outcome of Aim 1, demonstrates good internal consistency (alpha=.74) and is routinely used as the primary outcome measure in insomnia RCTs.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Insomnia Chronic</condition>
  <condition>Insomnia</condition>
  <condition>Insomnia, Primary</condition>
  <condition>Depression</condition>
  <condition>Depressive Symptoms</condition>
  <arm_group>
    <arm_group_label>CBT-I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy for Insomnia (CBT-I)</intervention_name>
    <description>Subjects receive 6-8 CBT-I sessions in an individual format.</description>
    <arm_group_label>CBT-I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Insomnia Severity Index &gt; 14&#xD;
&#xD;
          -  Meet diagnostic criteria for Insomnia&#xD;
&#xD;
          -  Meet diagnostic criteria for Major Depressive Disorder&#xD;
&#xD;
          -  Either currently taking an SSRI/SNRI or no antidepressant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Those with unstable medical conditions defined by change in diagnosis or medication in&#xD;
             past 2 months&#xD;
&#xD;
          -  Those with clinically significant comorbid psychiatric conditions (e.g., Bipolar&#xD;
             disorder)&#xD;
&#xD;
          -  Those with known untreated sleep apnea or other clinically significant sleep disorder&#xD;
             other than insomnia&#xD;
&#xD;
          -  Those currently taking medications that affect sleep or metabolism (e.g., stimulants,&#xD;
             thyroid meds)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul W Gunter, M.S.</last_name>
    <phone>215-746-1258</phone>
    <email>paul.gunter@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W Gunter, M.S.</last_name>
      <phone>215-746-1258</phone>
      <email>paul.gunter@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism</keyword>
  <keyword>Metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

